With the fact that hyperactivation of genes involved in Hippo/YAP signaling–RTKs-positive feedback loop occurring in most advanced/recurrent cervical cancer patients (>70%) (9, 49, 52) and directly targeting the HPV-16 E6 has been shown to be ineffective for invasive cancer by itself alone (8), target inhibition of ST6GAL1 may be a promising combinational therapeutic strategy for RTK inhibitors or E6-directed therapies in cervical cancer. The gene discussed is ST6GAL1; the disease is cervical cancer.